Use of hyaluronidase e.g. as a drug for the treatment of profibrotic metabolic disorder, fibrotic liver disease, chronic viral liver disease, portal hypertension, chronic hepatitis C and hepatocellular carcinoma

摘要

#CMT# #/CMT# Use of hyaluronidase (I) as a drug for the treatment of liver disease with profibrotic metabolic disorder, is claimed. #CMT#ACTIVITY : #/CMT# Hepatotropic; Cerebroprotective; Hypotensive; Cytostatic; Antiinflammatory; Virucide; Metabolic. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# (I) is useful as a drug for the treatment of profibrotic metabolic disorder, fibrotic liver disease, chronic viral liver disease, portal hypertension and hepatocellular carcinoma. (I) in combination with peginterferon alpha and ribavirin, is useful for the treatment of chronic hepatitis C. (I) is useful in a hepatic portal system (all claimed). No biological data given. #CMT#ADVANTAGE : #/CMT# (I) in combination with peginterferon-alpha and ribavirin, reduces serious adverse effects (e.g. anemia and neutropenia). (I) increases tolerability of antiviral therapy. #CMT#ADMINISTRATION : #/CMT# Administration of (I) is 1-100000 IU per kg body weight, parenterally or locally, for one day (claimed).